Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹71.097 Cr
verified against source
Revenue YoY
42%
reported change
EBITDA
₹26.236 Cr
latest reported figure
Source
nse announcements
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Sakar Healthcare delivered a strong Q4 FY26 with revenue of ₹71.1 crore (+42% YoY), EBITDA of ₹26.2 crore (37% margin), and PAT of ₹11.0 crore (+91% YoY). The oncology division contributed 38% of full-year revenue, up from 21% last year, driven by domestic growth and initial export traction. Management guided for ~40% revenue growth in FY27, targeting oncology revenue to double to ~₹200 crore, supported by 60+ signed contracts, 125 dossier filings, and tech transfers with Accord, Torrent, and others. The oncology facility (capacity utilization <30%) can scale to ₹800-1,000 crore with minimal capex. Risks include lumpy export order patterns and potential delays in regulatory approvals for the remaining seven Accord products.
Colored figures show movement against the previous available record.
Guidance to track
- Management expects to sustain ~40% YoY revenue growth in FY27, driven by oncology exports and tech transfers.
- Oncology revenue expected to double from ~₹96 crore in FY26 to ~₹200 crore in FY27, with exports becoming dominant.
- Full-year EBITDA margin of ~27-28% is sustainable and expected to improve as oncology mix increases.
- The Bada oncology facility can potentially generate ₹800-1,000 crore revenue at optimal utilization over 4-5 years without significant incremental capex.
Risks flagged
- Oncology exports are tender-driven and may not follow a smooth quarterly trajectory, making near-term revenue lumpy.
- Only 2 of 9 Accord tech transfers are commercialized; remaining 7 await EMA approval, which could slip.
- Middle East conflict could indirectly impact API costs and logistics, though management claims contractual pass-through.
Key quotes
- The benefits of these investments are now beginning to materialize.
- We have already signed more than 60 oncology business contracts with over 35 discussions currently ongoing.
- The accord intact portfolio alone comprising 10 oncology products to be manufactured by SAK represents a potential opportunity of rupees 50 cr to 100 cr.
Research modules